CAS 84057-95-4|Ropivacaine

Introduction:Basic information about CAS 84057-95-4|Ropivacaine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Common NameRopivacaine
CAS Number84057-95-4Molecular Weight274.401
Density1.0±0.1 g/cm3Boiling Point410.2±45.0 °C at 760 mmHg
Molecular FormulaC17H26N2OMelting Point144 - 146ºC
MSDS/Flash Point201.9±28.7 °C

Names

Name(S)-ropivacaine
SynonymMore Synonyms

Ropivacaine BiologicalActivity

DescriptionRopivacain is a potent sodium channel blocker and acts as a local anesthetic agent. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of regional anesthesia and neuropathic pain management[1].
Related CatalogSignaling Pathways >>Membrane Transporter/Ion Channel >>Sodium ChannelResearch Areas >>Cardiovascular DiseaseResearch Areas >>Neurological DiseaseSignaling Pathways >>Membrane Transporter/Ion Channel >>Potassium Channel
Target

IC50: sodium ion influx[1] IC50: 402.7 μM (TREK-1 in COS-7 cell's membrane)[2]

In VivoEpidural administration of Ropivacaine effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury[1]. Ropivacaine inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC)[2]. Ropivacaine prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats[2]. Ropivacaine inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs[2]. Animal Model: Adult Sprague-Dawley rats (300–400g)[1] Dosage: 1 μM Administration: Infusion (added to the perfusate reservoir) Result: Attenuated pressure-dependent increases in filtration coefficient (Kf).
References

[1]. Dene Simpson, et al. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65(18):2675-717.

[2]. Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10(1):e0117321.

[3]. Hye Won Shin, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth

[4]. Milan Patel, et al. Ropivacaine Inhibits Pressure-Induced Lung Endothelial Hyperpermeability in Models of Acute Hypertension. Life Sci. 2019 Apr 1;222:22-28.

Chemical & Physical Properties

Density1.0±0.1 g/cm3
Boiling Point410.2±45.0 °C at 760 mmHg
Melting Point144 - 146ºC
Molecular FormulaC17H26N2O
Molecular Weight274.401
Flash Point201.9±28.7 °C
Exact Mass274.204498
PSA32.34000
LogP3.11
Vapour Pressure0.0±1.0 mmHg at 25°C
Index of Refraction1.552
InChIKeyZKMNUMMKYBVTFN-HNNXBMFYSA-N
SMILESCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Storage condition-20℃

Safety Information

Hazard CodesXi
Risk PhrasesR36/37/38:Irritating to eyes, respiratory system and skin .
Safety Phrases36/37/39-26
WGK Germany3
RTECSLK8650000
HS Code2933399090

Customs

HS Code2933399090
Summary2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Synonyms

(S)-ROPIVACAINE HCL
(2S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide
(S)-ROPIVACAINE HYDROCHLORIDE
(S)ROPIVACAINE HYDROCHLORIDE
(S)-ROPIVACAINEHYDROCHLORIDE
UNII-V910P86109
(S)-(-)-ropivacaine
(-)-1-propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
Ropivacaine
Ropivacaine hydrochloride Monohydrate
(S)ROPIVACAINE HY DROCHLORIDE
2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-, hydrochloride, hydrate (1:1:1)
S-ROPIVACAINE HCL
Ropivacaine (hydrochloride Monohydrate)
(2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide
Ropivacaine API
(+-)-ropivacaine hydrochloride
(S)-ROPIVACAINEHCL
(S)-(-)-1-propyl-2',6'-pipecoloxylidide
S-ROPIVACAINEHCL
ROPACARAINEHCL
MFCD00864425
2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-
RopivacaineHcl/MesylateBase
Ropivacainehydrochloride
Naropin
Ropivacaine hydrochloride
(S)-(-)-1-propyl-2',6'-pipecoloxylidine hydrochloride monohydrate
l-N-n-Propylpipecolic acid-2,6-xylidide
ROPIVACAINE MESYLATER
(-)-1-Propyl-2',6'-pipecoloxylidide
UNII-7IO5LYA57N
(S)-ropivacaine hydrochloride hydrate
(S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide
Naropine
(S)-N-propylpiperidine-2-carboxylic acid 2,6-dimethylphenyl amide
ropivacaine hydrochloride hydrate
Ropivacaine HCl.H2O
Ropivacaine HCl
S-ROPIVACAINE HYDROCHLORIDE
(2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide hydrochloride hydrate
(2S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride hydrate
CAS 867-81-2|Sodium D-pantothenate
CAS 574-12-9|Isoflavone
Recommended......
TOP